Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics.
Oh Chan KwonWonho ChoiSoo Min AhnJi Seon OhSeokchan HongChang-Keun LeeBin YooMin-Chan ParkYong-Gil KimPublished in: Advances in rheumatology (London, England) (2024)
Second JAKi could be a therapeutic option in patients with difficult-to-treat RA who have failed to a JAKi and subsequent bDMARDs.